Danaher Corp DHR

$214.06 +2.30 (1.09%)

Valuation

Market cap
148,864,320,000
Revenue TTM
$24,568,000,000
Net income TTM
$3,614,000,000
PE ratio
27.28
Forward PE
25.99
Profit margin
14.71%
Debt to equity
0.48

Trading

Volume
3,915,800
Avg volume
4,124,520
Day's range
$211.98 – $216.06
Shares out
702,986,000
Stochastic %K
17%
Beta
0.76
Analysts
Strong Sell
Price target
$229.46

Price

Company profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of...

Show more

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
202 828 0850
Website
https://www.danaher.com
Address
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States

Latest news

Stocktwits

TiJr Oct 3, 6:57 PM
$CYCU How could Cycurion develop? The interesting parallels are $CSU.TSX , $ROP and $DHR, which built scale through disciplined acquisitions and strong operating platforms. CYCU is attempting a similar early-stage playbook: Acquire businesses → gain customers/contracts → cross-sell complementary services → grow recurring revenue → reinvest into more acquisitions. Digital Ally added 800+ customers, while Secuvant added cybersecurity capabilities. The key question is whether CYCU can turn these acquisitions into a repeatable growth flywheel without excessive dilution or leverage. Not saying CYCU becomes $CSU.TSX /$ROP/$DHR — just that their models show what’s possible if the platform strategy works. #CYCU #CSU #ROP #DHR #MAndA #RollUp #SmallCap
0 replies
astuteoptics1 Oct 2, 12:46 AM
$DHR Our framework on Danaher Corporation yields a bullish stance, with 8 of 9 matrix cells positive and an average conviction of 3.75 out of 5. As shown in the chart attached, the only neutral reading is long-term technical momentum after an extended drawdown. Across the rest of the grid, evidence is constructive: a second-quarter earnings beat paired with raised guidance anchors the near term, while abating headwinds benefit the intermediate horizon. Sentiment aligns as well, highlighted by a twenty percent decline in short interest alongside steady institutional backing, with price holding above the 200-day moving average. We would change our mind if renewed headwinds impair free cash flow or if price breaks below the 200-day average. This reflects our read as of 21 Sep 2026—a dated snapshot, not a live call. (Disclosure: we're @astuteoptics1 and this is our own research.)
0 replies
mpgolfpro Oct 1, 6:10 PM
$DHR Never fails. This thing goes up slowly then absolutely tanks. What a joke
2 replies
onlythebestcompanies Sep 30, 2:09 PM
$DHR $300 soon.
1 replies
TradeQuant Sep 30, 1:27 PM
$DHR Taking partial profits here.
1 replies
SmartFlowTrading Sep 25, 1:31 PM
Top 5 bullish options flow names on my watch 👇 1. $ALK — $908K in bought calls, ~22 DTE and near the money. Investor Day is Sep 29, so there is a clear catalyst sitting right inside the option window. 2. $SCHW — $679K in bought calls, ~19 DTE with aligned recent flow and no opposing print. Earnings Oct 15 — expiry selection matters here. 3. $DVN — $243K in near-ATM calls, ~13 DTE. All 3 filtered trades over the last 7 days are bullish. Cleaner setup, just smaller premium. 4. $NBIS — $1.42M bought call, ~36 DTE, but 19% OTM. Stock was already +7.4%, so this looks more like momentum positioning and comes with chase risk. 5. $DHR — $268K bought call, ~29 DTE and 5% OTM. Earnings Oct 21, just before the Oct 23 expiry. Event structure makes sense, but it is only one print. Flow is not a signal by itself ; I’m looking for price confirmation and follow-through.
0 replies
SunriseTrader Sep 22, 4:33 PM
$DHR daily updated chart. Next level watching is 223.50ish
1 replies
11thestate Sep 22, 1:06 PM
If you followed $DHR through its bioprocessing business, COVID-related demand assumptions, and repeated guidance cuts, there's an update worth knowing about. The $172.5M settlement is now reviewing late claims, subject to approval. Shareholders who held stock between 2022 and 2023 may still be able to participate, check your eligibility and submit your claim: https://11th.com/cases/danaher-investor-settlement
0 replies